"The demand for advanced veterinary diagnostics is surging, and we aim to leverage our market position to capture a larger share of this growing sector."
— Zomedica CEO
03Detailed Report
ZOM
Zomedica Corp
Period
Q1 2025
CurrencyUSD
Report TypeQuarterly Earnings
GeneratedJun 28, 2026
Swipe to view all report sections
Executive Summary
Zomedica Corp reported its Q1 2025 results, highlighting a revenue of $6.26 million, reflecting a year-over-year growth of 14.23%, but a quarter-over-quarter decline of 14.65%. The gross profit margin improved to 65.75%, which is a positive indicator amid challenging market conditions. Despite this, the company continues to post a significant net loss of $9.16 million, signaling ongoing operational challenges. Management expressed commitment to refining its product offerings and enhancing market penetration in its earnings call, underscoring a focus on growing diagnostic solutions for companion animals. Investors should monitor upcoming product launches as key drivers of market growth and potential profitability.
Key Performance Indicators
Revenue
Increasing
6.26M
QoQ: -14.65% | YoY: 14.23%
Gross Profit
Increasing
4.12M
65.75% margin
QoQ: 28.54% | YoY: 7.35%
Operating Income
Decreasing
-10.39M
QoQ: 8.81% | YoY: -38.26%
Net Income
Decreasing
-9.16M
QoQ: 59.12% | YoY: -43.46%
EPS
Decreasing
-0.01
QoQ: 59.39% | YoY: -43.08%
Revenue Trend
Margin Analysis
Financial Highlights
Revenue Growth: Zomedica's revenue of $6.26 million for Q1 2025 represents a 14.23% increase year-over-year, showcasing the strong demand for its veterinary diagnostics products. However, the QoQ decrease of 14.65% raises questions about seasonal fluctuations and ongoing operational efficiencies.
Profitability Metrics: The gross profit margin saw an improvement to 65.75%, up from 62.48% in Q4 2024. However, the net income for the quarter was a loss of $9.16 million, reflecting a -43.46% change year-over-year, underscoring persistent cost management issues that must be addressed.
Cash Position: As of the end of Q1 2025, Zomedica had $10.94 million in cash and cash equivalents, down from $12.95 million at the beginning of the quarter. The total assets stood at $243.7 million, supported by a solid current ratio of 11.50.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
6.26M
14.23%
-14.65%
Gross Profit
4.12M
7.35%
28.54%
Operating Income
-10.39M
-38.26%
8.81%
Net Income
-9.16M
-43.46%
59.12%
EPS
-0.01
-43.08%
59.39%
Key Financial Ratios
Gross Profit Margin
Excellent
65.70%
Gross profit margin is exceptional, indicating strong pricing power and operational efficiency
Operating Profit Margin
Weak
-1.66%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-1.46%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.04%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.04%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
11.50
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
Conservative
0.01
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-3.74x
Negative earnings make P/E ratio not meaningful
Price to Book
Undervalued
0.59x
Trading below book value, potential value opportunity or distressed
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.